Literature DB >> 848505

Hyperuricosuria in the Fanconi syndrome.

A D Meisel, H S Diamond.   

Abstract

A patient with asymptomatic adult Fanconi syndrome with glycosuria, amino-aciduria, hypophosphatemia, and renal tubular acidosis was found to have hypouricemia (serum uric acid, 1.5-1.8 mg/100 ml) secondary to increased renal clearance of urate (urate clearance/glomerular filtration rate, 32 per cent). Increased urate clearance in this patient with multiple reabsorptive defects probably represents diminished urate reabsorption. Consistent with this, the uricosuric response to probenecid was diminished. Reabsorption of filtered urate appeared to be intact. Inhibition of urate secretion with pyrazinamide completely suppressed the uricosuria in this patient, suggesting that increased urate clearance was due to either enhanced secretion or diminished reabsorption of secreted urate. There was no direct evidence for increased urate secretion. The response of urate excretion to pharmacologic inhibitors of tubular transport of urate differs in various clinical states associated with hyperuricosuria. The responses may reflect different mechanisms of hyperuricosuria.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 848505     DOI: 10.1097/00000441-197701000-00013

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Clinical and functional characterization of URAT1 variants.

Authors:  Velibor Tasic; Ann Marie Hynes; Kenichiro Kitamura; Hae Il Cheong; Vladimir J Lozanovski; Zoran Gucev; Promsuk Jutabha; Naohiko Anzai; John A Sayer
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

2.  Functional Urate-Associated Genetic Variants Influence Expression of lincRNAs LINC01229 and MAFTRR.

Authors:  Megan Leask; Amy Dowdle; Hamish Salvesen; Ruth Topless; Tayaza Fadason; Wenhua Wei; William Schierding; Judith Marsman; Jisha Antony; Justin M O'Sullivan; Tony R Merriman; Julia A Horsfield
Journal:  Front Genet       Date:  2019-01-21       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.